“We have valued Sol-Gel based on a discounted cash flow (DCF)-based analysis. This yields a value of $102M for TWIN, assuming a 50% probability of success, and a $323M valuation for VERED, assuming a 60% probability of success.”,” HC Wainwright’s analyst commented.
Several other research firms have also commented on SLGL. Zacks Investment Research upgraded Sol Gel Technologies from a sell rating to a hold rating in a research report on Friday, June 22nd. ValuEngine upgraded Sol Gel Technologies from a hold rating to a buy rating in a research report on Monday, August 20th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $19.00.
Shares of SLGL traded up $0.04 during midday trading on Wednesday, hitting $6.88. 2,200 shares of the stock were exchanged, compared to its average volume of 37,224. Sol Gel Technologies has a 52-week low of $6.03 and a 52-week high of $16.48. The firm has a market cap of $128.67 million and a P/E ratio of -1.37.
Sol Gel Technologies (NASDAQ:SLGL) last released its quarterly earnings results on Wednesday, August 8th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.12. The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.05 million. research analysts expect that Sol Gel Technologies will post -1.97 earnings per share for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Delek Group Ltd. purchased a new position in Sol Gel Technologies in the first quarter valued at $10,703,000. Nexthera Capital LP purchased a new position in Sol Gel Technologies in the first quarter valued at $5,334,000. Guggenheim Capital LLC purchased a new position in Sol Gel Technologies in the first quarter valued at $1,073,000. DAFNA Capital Management LLC purchased a new position in Sol Gel Technologies in the first quarter valued at $361,000. Finally, Alpine Global Management LLC purchased a new position in Sol Gel Technologies in the second quarter valued at $118,000. Institutional investors and hedge funds own 22.26% of the company’s stock.
About Sol Gel Technologies
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.